Quote:

---

"Tiny, one more point to add to your great breakdown. Of the 4 women who are still alive, three of them were treated with atezolizumab in addition to LL. Atezolizumab, commercially known as Tecentriq, is a check-point inhibitor made by Genentech.

This means that the next study will likely use this combination on everyone in the treatment group which should lead to a significant increase in the percentage of women who ultimately become cancer free.

---

The use of other drugs would be up to the physician. Tencentriq is a Pd=L1 blocker like Keytruda. Since leronlimab already downregulates PD-1/PD-L1 it wouldn't have added much to the results. Most likely some of the women who did not survive were also using PD-L1 blockers given their popularity for treatment. I doubt they'll be added to the protocol for a new trial although their use will probably be allowed in the protocol as will other drugs of the doctor's choice.